Pinheiro, Bernardete <br/><br/>
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.  [electronic resource] 

 -  Journal of medical economics  May 2020 
 - 484-491 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2020.1717499  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age of Onset<br/>Cladribine--adverse effects<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Female<br/>Fingolimod Hydrochloride--adverse effects<br/>Health Expenditures--statistics & numerical data<br/>Health Resources--economics<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Male<br/>Markov Chains<br/>Middle Aged<br/>Models, Economic<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Portugal<br/>Quality-Adjusted Life Years